Verona Pharma PLC American Depositary Share’s (VRNA) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other brokerages have also recently weighed in on VRNA. Wells Fargo & Company cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and reduced their price target for the stock from $138.00 to $107.00 in a research note on Thursday, July 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price target on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday. Zacks Research raised Verona Pharma PLC American Depositary Share to a “hold” rating in a research note on Friday, August 8th. HC Wainwright reaffirmed a “neutral” rating and issued a $107.00 price target (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, July 14th. Finally, Roth Capital cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Two equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $109.00.

Verona Pharma PLC American Depositary Share Price Performance

Shares of Verona Pharma PLC American Depositary Share stock opened at $106.91 on Wednesday. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87. The company has a market cap of $9.21 billion, a PE ratio of -107.99 and a beta of 0.05. The business has a 50 day moving average of $106.09 and a 200 day moving average of $89.08. Verona Pharma PLC American Depositary Share has a 52 week low of $31.09 and a 52 week high of $106.93.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.14. The company had revenue of $103.14 million for the quarter, compared to analysts’ expectations of $90.41 million. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%. As a group, equities research analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current year.

Insider Transactions at Verona Pharma PLC American Depositary Share

In related news, Director Vikas Sinha sold 4,328 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $56,869.92. Following the sale, the director directly owned 94,112 shares of the company’s stock, valued at $1,236,631.68. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David R. Ebsworth sold 1,904 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $25,018.56. Following the sale, the director directly owned 880,499 shares in the company, valued at $11,569,756.86. This trade represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 540,584 shares of company stock valued at $7,103,274. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Verona Pharma PLC American Depositary Share

Institutional investors have recently modified their holdings of the business. Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the first quarter valued at $284,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Verona Pharma PLC American Depositary Share by 366.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,486 shares of the company’s stock valued at $720,000 after buying an additional 9,021 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Verona Pharma PLC American Depositary Share by 14.0% during the first quarter. GAMMA Investing LLC now owns 1,837 shares of the company’s stock valued at $117,000 after buying an additional 225 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at $389,000. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at $1,492,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.